KAI-4729

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameKAI-4729
Drug Alias NameHRS-4729KAI-4729
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon receptorGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsOverweightObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Tuojie Biomedical Technology Co LtdHercules CM NewCoFujian Suncadia Medicine Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsOverweightObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A